Shares of WUXI BIO, a leading global provider of biologic drug development and manufacturing services, soared 16.33% to close at HK$78.50 on the Hong Kong Stock Exchange on Thursday. The significant rally pushed the stock to a new 52-week high, driven by reports that its subsidiary WuXi Biologics (Cayman) and affiliate WuXi AppTech are planning to sell their cell and gene therapy manufacturing unit, WuXi Advanced Therapies.
The divestment plan is seen as a strategic move by WUXI BIO to address the tightening scrutiny and restrictions imposed by the United States on Chinese companies involved in biotechnology and advanced manufacturing due to national security concerns. By offloading these operations, WUXI BIO aims to mitigate potential regulatory hurdles and risks associated with its US business.
Analysts view this decision as a proactive step by WUXI BIO to protect its core business and maintain its strong foothold in the global biopharmaceutical market. The company's commitment to compliance and adaptability in the face of geopolitical tensions has been well-received by investors, as evidenced by the significant stock price surge.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。